Abstract 1591P
Background
Gastric cancer (GC) is 5th most common cancer and 4th most common cause of cancer death worldwide. The rate of GC in patients < 40 years in different countries is ∼ 5%. The incidence and characteristics of GC in <40 patients were not studied in Georgian population. We analyzed clinicopathologic features of early onset GC in Georgia.
Methods
In this study we analyzed data from national cancer registry of Georgia 2015-2021. The data included number of cases, age, sex, anatomic location, stage, pathology and treatment types of GC. Aim of the study was to investigate clinicopathologic characteristics, treatment approaches and survival rates of GC in patients <40 compared to entire cohort. Survival was summarized by Kaplan-Meier method.
Results
A total of 1775 patients with GC were included in the study during 2015-2021. Out of 1775 patients 52 (2,9%) were < 40 years. Median age 34 (17-39). In <40 patients 50% were female, while in entire cohort 62% were male. No differences were seen in anatomic location, tumor grade, stage. Stage III (25 % in <40 patients vs 29% in entire cohort) and IV (40% vs 43%) were most common. Differences were seen in pathologic types - not otherwise classified adenocarcinoma 31% in <40 patients vs 25% in entire cohort (P value 0.3367), not otherwise classified carcinoma 26 % vs 2% (P value <0.0001), signet ring carcinoma 17% vs 6% respectively (P value 0.0004). In entire cohort rate of undifferentiated carcinoma was 30% and tubular adenocarcinoma 16%, which were not seen in <40 patients. 23% of <40 patients vs 30% entire cohort had surgery (P value 0.2294) and 42% vs 30% chemotherapy (P value 0.0714). Median overal survival (OS) for patients <40 was 20 months (95% CI 9,0-30,0) and 13 months for entire cohort (95% CI 12,0-15,0) (p value – 0,1488).
Conclusions
This study showed, that in Georgian <40 patients GC is equally distributed between both sexes, while in the entire cohort it is slighlty more common in males. Pathologic types as not otherwise classified carcinoma and signet ring carcinoma were seen most frequently in <40 patients. <40 patients were slightly more likely to receive chemotherapy and surgery. However, median OS was <2 years for patients <40. Further studies are required to understand causes of early onset GC in Georgian patients and to improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T. Esakia.
Funding
Has not received any funding.
Disclosure
E. Smyth: Financial Interests, Personal, Invited Speaker: Amgen, Bristol Myers Squibb, Imedex, Merck, Novartis, Prova Education, Servier, TouchIME, Elsevier, PeerVoice, Cor2Ed, Daiichi Sankyo; Financial Interests, Personal, Other, TSC: Amgen; Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Bristol Myers Squibb, Bristol Myers Squibb, My Personal Therapeutics, Novartis, Roche, Servier, Zymeworks, Viracta; Financial Interests, Personal, Other, IDMC: BeiGene, Zymeworks; Financial Interests, Personal, Other, IDMC chair: Everest Clinical Research; Financial Interests, Personal, Officer: EORTC GI Clinical Trials Group; Financial Interests, Institutional, Local PI: Daiichi Sankyo, Merus, Basilea, MSD, Mirati; Financial Interests, Institutional, Coordinating PI: Roche, AstraZeneca, Amgen; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Non-Financial Interests, Leadership Role, Trustee: UK & Ireland Oesophagogastric Group (UKIOG). All other authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22